Effect of Pregnancy and Zidovudine Therapy on Viral Load in HIV-1-Infected Women
- 1 March 1997
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 14 (3) , 232-236
- https://doi.org/10.1097/00042560-199703010-00006
Abstract
The objective of this study was to determine the effect of pregnancy and zidovudine (ZDV) on viral load in HIV-1 infected women. A prospective nonrandomized cohort study was conducted at a university medical center and affiliated clinic and included 44 HIV-1-seropositive pregnant women seen between June 1991 and September 1995. Twenty-three women initiated ZDV therapy during their pregnancy. Seventeen women did not take antiretrovirals, and four women took ZDV prior to and throughout pregnancy. HIV-1 viral load as determined by quantitative peripheral blood mononuclear cell (PBMC) culture and quantitative plasma RNA levels was measured at various times during pregnancy and in the postpartum period. HIV-1 load, by both infectivity and RNA levels, was relatively low and remained stable during pregnancy and through 6 weeks post partum. Initiation of ZDV therapy during pregnancy did not result in a significant decrease in viral load at delivery when controlling for the effect of pregnancy. In those women who received ZDV therapy only during pregnancy, there was a trend toward an increase in viral load measured by PBMC infectivity 6 months post partum compared with the levels before the initiation of ZDV. Mother-to-child transmission of HIV-1 occurred in one of 27 (4%) ZDV-treated women and in two of 16 (12.5%) untreated women. Among HIV-1-infected pregnant women with low viral levels, HIV-1 plasma RNA and infectivity remained stable during and after gestation. Although these results are based on a relatively small number of women and should be considered preliminary, the lack of significant ZDV-associated diminution in viral levels suggests that the protective effect of ZDV on the mother-to-child transmission of HIV-1 may not be due to the reduction in maternal viral levels but, by inference, may be due to the prevention of HIV-1 reverse transcription in the newborn.Keywords
This publication has 12 references indexed in Scilit:
- Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral loadJAMA, 1996
- Effects of Zidovudine Use During Pregnancy on Resistance and Vertical Transmission of Human Immunodeficiency Virus Type 1Clinical Infectious Diseases, 1995
- Reduction of Maternal-Infant Transmission of Human Immunodeficiency Virus Type 1 with Zidovudine TreatmentNew England Journal of Medicine, 1994
- Quantitation of human immunodeficiency virus type 1 during pregnancy: relationship of viral titer to mother-to-child transmission and stability of viral load.Proceedings of the National Academy of Sciences, 1994
- Factors predictive of maternal-fetal transmission of HIV-1. Preliminary analysis of zidovudine given during pregnancy and/or deliveryPublished by American Medical Association (AMA) ,1994
- Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reactionAIDS, 1993
- Influence of pregnancy on human immunodeficiency virus diseaseEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 1990
- A Semiquantitative Microassay for Measurement of Relative Number of Blood Mononuclear Cells Infected with Human Immunodeficiency VirusAIDS Research and Human Retroviruses, 1990
- Serious infections during pregnancy among women with advanced human immunodeficiency virus infectionAmerican Journal of Obstetrics and Gynecology, 1990
- Prospective study of human immunodeficiency virus infection and pregnancy outcomes in intravenous drug usersJAMA, 1989